SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
June 19 2015 - 2:00AM
Business Wire
- The research published by Professor
Thanos Tzounopoulos of the University of Pittsburgh and Professor
Anastasios V. Tzingounis of the University of Connecticut, along
with Drs. Scott Edwards and Takeru Furuya of SciFluor, found that
SF0034 is a clinical candidate for treating epilepsy and preventing
tinnitus.
- Publication of this seminal paper
entitled, “Potent KCNQ2/3-Specific Channel Activator Suppresses In
Vivo Epileptic Activity and Prevents the Development of Tinnitus,”
illustrates SciFluor’s approach of collaborating with leading
academic institutions to advance its drug discovery pipeline.
SciFluor Life Sciences, an emerging clinical stage
biopharmaceutical company that creates innovative therapeutics for
patients suffering from a variety of diseases, announced
that pre-clinical research demonstrating the potential
effectiveness of its patented novel compound, SF0034, for treating
epilepsy and preventing tinnitus was published in the peer-reviewed
publication, The Journal of Neuroscience.
The article entitled, “Potent KCNQ2/3-Specific Channel Activator
Suppresses In Vivo Epileptic Activity and Prevents the Development
of Tinnitus” was published in the June 10th issue of the Journal,
and was authored by Professor Thanos Tzounopoulos, Department of
Otolaryngology and Neurobiology, University of Pittsburgh and
Professor Anastasios V. Tzingounis, Department of Physiology and
Neurobiology, University of Connecticut along with Drs. Scott
Edwards and Takeru Furuya of SciFluor.
“Publication in such a highly regarded peer-reviewed journal is
significant validation for SciFluor as the company ramps up for
clinical testing of SF0034,” said Omar Amirana, MD, SciFluor Chief
Executive Officer and Senior Vice President of Allied Minds, parent
company of SciFluor.
SciFluor develops differentiated, best-in-class compounds based
on fluorine chemistry for the creation of novel therapeutics to
treat a variety of diseases, including retinal disease, CNS
disorders and inflammatory disease. The company currently holds
patents for SF0034 as well as for SF0166, a drug that is designed
to be administered topically to treat retinal diseases.
The publication highlights the benefits of SF0034, a potassium
channel activator, over retigabine, a U.S. Food and Drug
Administration-approved drug indicated for the treatment of
epilepsy. SF0034 was found to have significantly greater potency
and selectivity compared to retigabine. The pre-clinical efficacy
data from multiple in vivo models of epilepsy and tinnitus
described in this publication led the authors to conclude that
SF0034 is a valuable clinical candidate for treating epilepsy and
preventing tinnitus.
Scott Edwards, Ph.D., Vice President and General Manager of
SciFluor, said, “The publication of this article is the culmination
of a productive collaboration with Professors Tzounopoulos and
Tzingounis that has provided key pharmacological and behavioral
data demonstrating SF0034’s potential to become a best-in-class
drug for treating epilepsy and tinnitus by selectively activating
the neuronal potassium channel, KCNQ2/3.”
Dr. Edwards is the lead on the SF0034 therapeutic program, which
is also being evaluated for therapeutic potential for other
diseases such as amyotrophic lateral sclerosis (ALS, or Lou
Gehrig’s disease). Additional university authors on the paper
included Bopanna I. Kalappa of the University of Pittsburgh, and
Heun Soh and Kevin M. Duignan of the University of Connecticut.
SciFluor is a subsidiary of Allied Minds (LSE: ALM). More
information about the company can be found at www.scifluor.com.
About SciFluor Life SciencesSciFluor Life Sciences is a
drug discovery company applying expertise in fluorine chemistry
to create a broad portfolio of differentiated
best-in-class therapeutics to treat various diseases. The
company creates patentable new chemical entities
(NCEs) directed towards precedented biological targets. SciFluor
strategically incorporates fluorine or fluorine-containing
groups to design drugs with improved pharmacological profiles
that provide important benefits over existing therapies such
as improved safety, efficacy, dosing, and patient compliance.
This capital-efficient and de-risked drug discovery approach
has resulted in the generation of a proprietary pipeline of
novel and differentiated small molecule drugs across
a diverse range of therapeutic categories and
disease areas, including retinal disease, CNS
disorders, pain, pulmonary and inflammatory
disease. More information about SciFluor can be found at
www.scifluor.com.
About Allied MindsAllied Minds (LSE: ALM) is an
innovative U.S. science and technology development and
commercialization company. Operating since 2006, Allied Minds
forms, funds, manages and builds products and businesses based on
innovative technologies developed at leading U.S. universities and
federal research institutions. Allied Minds serves as a diversified
holding company that supports its businesses and product
development with capital, central management and shared services.
More information about the Boston-based company can be found
at www.alliedminds.com.
Allied Minds Forward-Looking StatementThis press release
contains statements that are or may be forward-looking statements,
including statements that relate to the company’s future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
company’s regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law,
regulatory requirement, the Listing Rules and the Disclosure and
Transparency Rules, neither the company nor any other party intends
to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150618006431/en/
ArcPoint Strategic CommunicationsChristine Dunn, 617-484-1660,
x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2024 to May 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From May 2023 to May 2024